An interesting article in this issue of Läkartidningen argues for the benefit of a broad HPV vaccination with catch-up vaccination also for men, and sheds more light on HPV-related cancer in men. There has been an increase of HPV-related anal and oropharyngeal cancer in recent years, but no screening methods for these cancers have been implemented. A gender neutral catch-up vaccination would help to decrease the burden of oncogenic HPV in society, and would also be beneficial for females. Swedish authorities have now come to the conclusion that catch-up vaccination of men would be cost-effective, a decision that we strongly support.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Are we hopefully on the way to eradicating HPV-related cancer?].
Lakartidningen
March 2025
docent, överläkare, dermatologi och venereologi, Karolinska universitetssjukhuset, Stockholm; institutionen för medicin, Karolinska institutet.
An interesting article in this issue of Läkartidningen argues for the benefit of a broad HPV vaccination with catch-up vaccination also for men, and sheds more light on HPV-related cancer in men. There has been an increase of HPV-related anal and oropharyngeal cancer in recent years, but no screening methods for these cancers have been implemented. A gender neutral catch-up vaccination would help to decrease the burden of oncogenic HPV in society, and would also be beneficial for females.
View Article and Find Full Text PDF[Catch-up vaccination prevents HPV infection and related precancers when given up to age 26].
Lakartidningen
March 2025
docent, överläkare, Karolins-ka universitetssjukhuset, Stockholm.
HPV-related cancers in men, particularly anal and oropharyngeal cancers, are increasing in Sweden and globally. Men who have sex with men, trans persons and people living with HIV are at especially high risk. HPV vaccination effectively prevents HPV infection and related precancers when given up to age 26.
View Article and Find Full Text PDFCost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study.
Lancet Reg Health West Pac
March 2025
School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background: Several domestically-manufactured nonavalent HPV vaccine candidates are in phase III clinical trials and their future availability may address the current dilemma of insufficient supply and high price of the overseas-manufactured nonavalent HPV vaccine in China. We compare the population-level effectiveness and cost-effectiveness of switching to nonavalent HPV vaccination in China.
Methods: We used a previously validated transmission model to project the lifetime costs and effectiveness of five same-vaccine and two mixed-vaccine strategies.
Spatial analysis of measles cases and vaccination coverage in the Somali region, eastern Ethiopia.
Front Epidemiol
February 2025
Public Health Department, Institute of Health Science, Jigjiga University, Jigjiga, Ethiopia.
Background: Measles is a major public health concern that causes morbidity and mortality among children. In 2019, measles incidence reached its highest level in 23 years, with low measles containing vaccine dose one coverage playing a vital role. It can be prevented by two doses of the measles vaccine, either alone or in combination with measles-rubella (MR), which is a low-cost strategy for lowering morbidity and mortality among children.
View Article and Find Full Text PDFRacial and Ethnic Disparities in Human Papillomavirus Vaccination Among US-Born and Foreign-Born Adults Aged 18 to 26 Years in the United States.
Vaccines (Basel)
January 2025
Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine, Houston, TX 77030, USA.
Background/objectives: Human papillomavirus (HPV) is linked to multiple cancers that can be prevented through vaccination. While the optimal age for vaccination is in childhood and adolescence, vaccination recommendations include adults through age 26 who missed childhood/adolescent vaccination. There are limited data about disparities among adults eligible for catch-up HPV vaccination.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!